These data support the application of androgenic compounds such as the nonsteroidal selective AR modulator (SARM) enobosarm, which decreases the growth of some ERα-positive breast cancers [72], and they form the rationale for the clinical testing of SARMs for the treatment of some breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.